Log In
BCIQ
Print this Print this
 

galcanezumab (LY2951742)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHumanized mAb targeting calcitonin gene-related peptide (CGRP)
Molecular Target Calcitonin gene-related peptide (CGRP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMigraine
Indication DetailsPrevent cluster headaches; Prevent episodic migraine
Regulatory Designation U.S. - Fast Track (Prevent cluster headaches)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/17/2011

Undisclosed

0

Undisclosed

Get a free BioCentury trial today